PALI
Palisade Bio Inc
NASDAQ: PALI · HEALTHCARE · BIOTECHNOLOGY
$1.87
+3.76% today
Updated 2026-06-03
Market cap
$293.69M
P/E ratio
14.08
P/S ratio
11.78x
EPS (TTM)
$0.12
Dividend yield
—
52W range
$1 – $3
Volume
4.0M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C7.3
Quality
B+3.0
Profitability
D6.0
Valuation
B3/9
Piotroski F-Score
Weak
14.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$9.71
+419.25%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 14.79 — safe zone
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-3.89M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $250000.00 | $250000.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-14.26M | $-12.30M | $-14.44M | $-16.78M | $-9.60M |
| EPS | — | — | — | — | $0.12 |
| Free cash flow | $-13.37M | $-11.14M | $-12.19M | $-10.85M | $-3.89M |
| Profit margin | -5,704.00% | -4,920.00% | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-12 | JONES, MITCHELL LAWRENCE | Sale | 1,989 | $1.75 |
| 2026-02-12 | FINLEY, JOHN DAVID | Sale | 3,896 | $1.75 |
| 2026-02-11 | JONES, MITCHELL LAWRENCE | Sale | 8,000 | — |
Peer comparison
Smart narrative
Palisade Bio Inc trades at $1.87. representing a P/E of 14.08x trailing earnings. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 14.79, it sits in the safe zone.
Frequently asked questions
What is Palisade Bio Inc's stock price?
Palisade Bio Inc (PALI) trades at $1.87, on a P/E of 14.1x and a P/S of 11.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Palisade Bio Inc overvalued?
Palisade Bio Inc carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Palisade Bio Inc (PALI)?
The 12-month analyst consensus target is $9.71, about 419.3% above the current $1.87. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Palisade Bio Inc's Altman Z-Score is 14.79, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio11.78x
ROE-18.96%
Beta1.53
50D MA$2.00
200D MA$1.74
Shares out0.17B
Float0.13B
Short ratio—
Avg volume4.0M
Performance
1 week-9.58%
1 month+8.50%
3 months+13.61%
YTD-7.66%
1 year—
3 years—
5 years—